DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Reardon DA, Schuster J, Tran DD. et al.
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
J Clin Oncol 2015;
33: abstr 2009
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.